Table 2. Risk factors.
No. of event | Observed person-years | ID | Crude HR | 95% C.I. | Adjusted HR¶ | 95% CI | |||
---|---|---|---|---|---|---|---|---|---|
Lower | Upper | Lower | Upper | ||||||
Chronic periodontitis | |||||||||
No | 483 | 651,552 | 0.7 | 1 | 1 | ||||
Yes | 869 | 655,566 | 1.3 | 1.79** | 1.60 | 2.00 | 1.79** | 1.60 | 2.00 |
Age | |||||||||
<20 | 53 | 135,583 | 0.4 | 1 | 1 | ||||
20–39 | 339 | 518,847 | 0.7 | 1.67** | 1.25 | 2.23 | 1.56** | 1.16 | 2.10 |
40–64 | 747 | 549,571 | 1.4 | 3.48** | 2.63 | 4.60 | 2.82** | 2.11 | 3.78 |
≧65 | 213 | 103,117 | 2.1 | 5.28** | 3.91 | 7.14 | 3.67** | 2.66 | 5.05 |
Gender | |||||||||
Male | 352 | 615,103 | 0.6 | 1 | 1 | ||||
Female | 1,000 | 692,015 | 1.4 | 2.52** | 2.24 | 2.85 | 2.55** | 2.25 | 2.88 |
Monthly income | |||||||||
<NT $20,000 | 677 | 639,530 | 1.1 | 1 | 1 | ||||
NT $20,000–NT $40,000 | 384 | 359,006 | 1.1 | 1.01 | 0.89 | 1.15 | 0.94 | 0.82 | 1.07 |
>NT $40,000 | 291 | 308,582 | 0.9 | 0.89 | 0.78 | 1.02 | 1.02 | 0.88 | 1.18 |
Urbanization | |||||||||
Urban | 903 | 879,933 | 1.0 | 1 | 1 | ||||
Suburban | 381 | 354,024 | 1.1 | 1.05 | 0.93 | 1.18 | 1.07 | 0.94 | 1.20 |
Rural | 68 | 73,161 | 0.9 | 0.91 | 0.71 | 1.16 | 0.86 | 0.67 | 1.11 |
Hypertension | 266 | 149,842 | 1.8 | 1.89** | 1.65 | 2.16 | 0.99 | 0.84 | 1.15 |
Hyperlipidemia | 176 | 86,980 | 2.0 | 2.10** | 1.79 | 2.46 | 1.24* | 1.04 | 1.47 |
Chronic insomnia | 634 | 304,042 | 2.1 | 2.91** | 2.62 | 3.24 | 2.08** | 1.86 | 2.32 |
CCI† | |||||||||
0 | 839 | 999,322 | 0.8 | 1 | 1 | ||||
1 | 421 | 256,471 | 1.6 | 1.95** | 1.74 | 2.20 | 1.38** | 1.21 | 1.56 |
≧2 | 92 | 51,325 | 1.8 | 2.14** | 1.72 | 2.65 | 1.30* | 1.03 | 1.62 |
Notes:
Risk factor analysis of primary Sjögren’s syndrome development.
Charlson comorbidity index; ID: Incidence density, per 1,000 person-years.
Adjusted for age, gender, monthly income, urbanization, hypertension, hyperlipidemia, chronic insomnia, and Charlson comorbidity index.
p < 0.05.
p < 0.01.